Categories: News

Invesco ltd: Form 8.3 – Willis Towers Watson PLC

                                               

Form 8.3

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

1.       KEY INFORMATION

Name of person dealing (Note 1) Invesco Ltd.
Company dealt in Willis Towers Watson plc
Class of relevant security to which the dealings being disclosed relate (Note 2) Ordinary Shares IE00BDB6Q211
Date of dealing 15-01-2021
  1. INTERESTS AND SHORT POSITIONS
     
  2. Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
  Long Short
  Number   (%) Number        (%)
(1) Relevant securities 1,502,572        1.165%      2,900                  0.002%
(2) Derivatives (other than options)    
(3) Options and agreements to purchase/sell    
Total 1,502,572        1.165%      2,900                   0.002%

 Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security: Long Short
  No.   (%) Number        (%)
(1) Relevant securities    
 

(2) Derivatives (other than options)

   
 

(3) Options and agreements to purchase/sell

   
Total    

                                         

  1. DEALINGS (Note 4)
     
  2. Purchases and sales
 

Purchase/sale

 

Number of relevant securities

 

Price per unit (Note 52

Sale 314 206.65 USD
Purchase 1,131 206.65 USD

(b)      Derivatives transactions (other than options transactions)

Product name,

e.g. CFD

Nature of transaction

(Note 6)

Number of relevant securities

(Note 7)

Price per unit

(Note 5)

       

(c)      Options transactions in respect of existing relevant securities

(i)       Writing, selling, purchasing or varying

Product name,
e.g. call option
Writing, selling, purchasing, varying etc. Number of securities to which the option relates (Note 7) Exercise price Type, e.g. American, European etc. Expiry date Option money paid/received per unit (Note 5)
             

(ii)      Exercising

Product name,

e.g. call option

Number of securities Exercise price per unit (Note 5)
     

(d)      Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction

(Note 8)

Details Price per unit

(if applicable) (Note 5)

     

    2.       OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

Is a Supplemental Form 8 attached? (Note 9)                                            NO

Date of disclosure 18-01-2021
Contact name Sam Edwards
Telephone number +44 1491 416381
If a connected EFM, name of offeree/offeror with which connected N/A
If a connected EFM, state nature of connection (Note 10)  

Staff

Recent Posts

Massimo Group Signs Letter of Intent to Acquire 100% of AI technology company FST in Drive to Accelerate Its AI-Powered Mobility and Health Technology Strategy

GARLAND, Texas, Feb. 3, 2026 /PRNewswire/ -- Massimo Group (NASDAQ: MAMO) ("Massimo" or the "Company"),…

1 hour ago

Baysient Launches iDose® GEN7.0, Expanding Precision Dosing Platform to 16 Inflammatory Disease Indications

Next-Generation Decision Support Software Introduces Predictive Clinical Tools for Gastroenterology, Rheumatology, Dermatology, and PulmonologyFORT MYERS,…

1 hour ago

From the Founders of Fitbit: Introducing Luffu, Your Guardian for Family Health & Safety

After making personal health accessible to millions with Fitbit, James Park and Eric Friedman announce…

1 hour ago

Embla Medical hf: Interim Report Q4 and Full Year 2025

COPENHAGEN, Denmark, Feb. 3, 2026 /PRNewswire/ -- Announcement no. 5/2026 Interim Report Q4 and Full…

1 hour ago

UAE Partners with Colossal Biosciences to Protect Biodiversity and Champion the Future of Life on Earth

The collaboration positions the UAE as a global leader in conservation, driving pioneering initiatives in…

1 hour ago

Case Reports in Regrowth Announces Publication of Muhammad Qasim Observational Case Report and Invites Medical Review

New York, New York--(Newsfile Corp. - February 3, 2026) - Case Reports in Regrowth today…

2 hours ago